The mortality risk associated with higher hemoglobin: is the therapy to blame?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 18756292.
- Also identified by DOI 10.1038/ki.2008.263.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recent trials have demonstrated a trend for increased mortality when patients with end-stage renal disease (ESRD) or chronic kidney disease (CKD) are treated with erythropoietin-stimulating agents (ESAs) to hemoglobin levels higher than recommended (>13 g/dl). Recent studies suggest that higher doses of ESAs, in themselves, may be at least partly responsible for this mortality risk. This is important, as more than 90% of patients with ESRD and approximately 20% of patients with CKD receive ESAs. Two new studies address this.
Medical subject headings
- Erythropoietin
- Hemoglobins
- Kidney Failure, Chronic